Italian Physicians’ Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey

Unmet needs remain in later lines chronic myeloid leukemia (CML): the response rate and the overall survival of resistant patients in the chronic phase who changed a second-generation TKI in the second line with another TKI with similar action are usually poor, while the off-target toxicities and th...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical medicine 2023-08, Vol.12 (16), p.5267
Main Authors: Breccia, Massimo, Piciocchi, Alfonso, Abruzzese, Elisabetta, Cilloni, Daniela, Messina, Monica, Soddu, Stefano, Castagnetti, Fausto, Stagno, Fabio, Fazi, Paola, Iurlo, Alessandra, Caocci, Giovanni, Gozzini, Antonella, Intermesoli, Tamara, D’Adda, Mariella, Pane, Fabrizio
Format: Article
Language:English
Subjects:
Beliefs, opinions and attitudes
Brief Report
Chronic myeloid leukemia
Clinical medicine
Diagnosis
Drug therapy
Kinases
Leukemia
Mutation
Patient outcomes
Perceptions
Physicians
Thrombocytopenia
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Unmet needs remain in later lines chronic myeloid leukemia (CML): the response rate and the overall survival of resistant patients in the chronic phase who changed a second-generation TKI in the second line with another TKI with similar action are usually poor, while the off-target toxicities and the potential development of mutations increase. The recent approval of asciminib, a STAMP inhibitor, in the third line, has the potential to soon change the therapeutic algorithm for this subset of patients. Here, we report the results of a GIMEMA survey assessing the number of patients currently treated in the third line in Italy, the current approach in later lines by Italian physicians, and the future role of this drug according to the reason to switch to asciminib (resistance and/or intolerance), as well as the perceptions about the future position of this agent.
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm12165267